Investors & Media

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. We believe the quality and breadth of our product candidate pipeline, platform technology, strategic collaborations and scientific team will enable us to become a fully integrated biopharmaceutical company with a diversified portfolio of novel therapeutics for major diseases.

1:14 PM ET Jul 3, 2008
Price	$1.42
Change	+ 0.02
Day Range	$1.36 - $1.42
Volume	3,400

Market data powered by TurboFeed.
Delayed at least 15 minutes.

Get a detailed stock quote

2007 Annual Report and Form 10-K
( PDF, 540.3 KB)

Corporate Presentation
( PDF, 537.9 KB)

Latest News

Jul 3, 2008

Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference

Jun 19, 2008

Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference

Jun 16, 2008

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

Jun 3, 2008

Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)

View all releases »

Calendar of Events

Jul 8, 2008 at 2:30 PM ET

Fourth Annual Collins Stewart Growth Conference

View all events & presentations »

Sunesis is an innovative biopharmaceutical company focused on therapeutics for oncology and other unmet medical needs.

Listen to recent webcasts of presentation conference calls, earnings calls, and more.